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ARTICLE
Clinical Study
Off-treatment bone mineral density changes in
postmenopausal women receiving anastrozole for 5 years:
7-year results from the IBIS-II prevention trial
Ivana Sestak 1, Glen Blake2, Raj Patel3, Jack Cuzick1, Anthony Howell4, Robert Coleman5 and Richard Eastell5
BACKGROUND: Anastrozole has been associated with substantial accelerated bone mineral density (BMD) loss during active
treatment.
METHODS: One thousand four hundred and ten women were included in a BMD substudy and stratified into three strata according
to their baseline T-score at spine or femoral neck. The primary objective of this analysis was to investigate whether DXA BMD at the
spine and hip changed two years after treatment cessation (between years 5 and 7) in those who did not receive risedronate.
RESULTS: Five- and seven-year BMD data were available for a total of 528 women who did not receive risedronate. In women with
normal BMD at baseline, an increase in BMD at the lumbar spine after anastrozole withdrawal was observed 1.25% (95% CI 0.73 to
1.77) (P= 0.0004), which was larger than in those on placebo (0.14% (−0.29 to 0.56))). At the hip, BMD remained unchanged
between years 5 and 7 for those previously on anastrozole but continued to a decrease in those who had been randomised to
placebo (−1.35% (−1.70 to −0.98)).
CONCLUSIONS: These are the first results reporting BMD changes after stopping anastrozole in a breast cancer prevention setting.
Our results show that the negative effects of anastrozole on BMD in the preventive setting are partially reversible.
British Journal of Cancer https://doi.org/10.1038/s41416-020-01228-2
BACKGROUND
Aromatase inhibitors are the choice of adjuvant endocrine
treatment in postmenopausal women with early oestrogen
receptor positive breast cancer breast cancer. They have shown
superior efficacy and a better safety profile over tamoxifen in the
adjuvant setting.1–3 In the prevention setting, the MAP.3 trial4
investigated exemestane compared to placebo to reduce the risk
of developing breast cancer and reported significant bone mineral
density (BMD) loss at both the lumbar spine and total hip after 2
years of follow-up on exemestane compared to placebo.5 Overall,
no increases in fractures with exemestane were observed, but the
follow-up of 35 months was too short for firm conclusions
concerning this endpoint.
The International Breast cancer Intervention Study (IBIS-II) trial
compared anastrozole with placebo in postmenopausal women at
high risk of developing breast cancer. A significant 53% reduction
in breast cancer with anastrozole was found,6 with updated results
showing a continued effect of anastrozole with longer follow-up.7
A substudy of the IBIS-II trial investigated the effect of risedronate
on bone density and measured BMD regularly in all participants
included in this study.8 An initial analysis of the BMD data
confirmed a significant decrease in BMD at the lumbar spine and
total hip in women who were randomised to anastrozole when
compared to placebo.8 However, a significant improvement in
anastrozole-induced BMD loss at both sites was observed for
women with osteopenia and osteoporosis who were taking
risedronate. An updated analysis of the 5-year data showed that
in osteopenic women risedronate counterbalances the negative
effect of anastrozole at the lumbar spine but not the total hip.9
These updated results suggest that risedronate is most active and
beneficial in the first 2 years of treatment with regards to
preventing anastrozole-induced bone loss.
It is important to understand the effects of long-term aromatase
inhibitor therapy on changes in BMD in the preventive setting in
more detail. Here, we analysed the changes in BMD between 5
and 7 years after randomisation with the primary aim to evaluate
the recovery of BMD after stopping anastrozole when given alone
(without risedronate). A secondary aim was to investigate BMD
recovery in those given treatment with risedronate before
stopping anastrozole.
METHODS
Study design and participants
The IBIS-II trial recruited 3864 healthy, postmenopausal women at
increased risk of breast cancer and randomised them to receive
either 1 mg/day anastrozole or matching placebo.6 Eligible
women were offered the opportunity to enter the bone substudy.
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One thousand four hundred and ten women entered the bone
substudy and were stratified into three groups according to the
lowest baseline T-score at either femoral neck or lumbar spine
(Fig. 1). Women with healthy T-score (≥−1.0) were entered into
stratum I and were monitored only (N= 761). Women who were
osteopenic (−2.5 ≤ T-score <−1.0) were entered into stratum II
and were randomised to receive risedronate (35 mg/week) or
matching placebo for five years (N= 500). Finally, osteoporotic
women with a T-score <−2.5 but greater than −4.0 or those with
one to two low trauma fragility fractures (as assessed by spinal
radiographs) were entered into stratum III and were required to
take risedronate (35 mg/week) (N= 149) (Fig. 1). Full inclusion/
exclusion criteria for the bone substudy were reported elsewhere.8
Our primary analysis (grey shaded boxes in Fig. 1) cohort
focuses on women with BMD evaluations at both years 5 and 7
who were randomised to anastrozole or placebo and did not
receive risedronate during the five years of active follow-up
(stratum I and II). Those who were either randomised or given
risedronate for five years (stratum II and stratum III) are referred to
as the secondary analysis population (Fig. 1). The trial was
approved by the UK North West Multicentre Research Ethics
Committee and was done in accordance with the Declaration of
Helsinki, under the principles of good clinical practice. Participants
provided written informed consent.
Assessments
All women entering the main IBIS-II study had a dual energy X-ray
absorptiometry (DXA) scan prior to study entry, with further
assessments by DXA scans at the lumbar spine and total hip at 12,
36, 60 and 84 months. This analysis focuses on the BMD changes
between 60 and 84-month follow-up points. At the 60-month
follow-up point, participants stopped with their allocated treat-
ment. T-scores have been calculated using either the Lunar10 or
Hologic11 manufacturer’s reference ranges for the lumbar spine
(L1–L4) and the NHANES III reference range for the femoral neck
region.12 All DXA scans were reviewed centrally by two clinical
scientists with expertise in bone densitometry (GB and RP) to
ensure quality assurance. Both assessors were blinded to
randomised treatment allocation.
Statistical analysis
All analyses were performed on a per protocol basis, in which
women were only included if a baseline, 5- and 7-year DXA scan
were available. The primary objective was to compare the changes
in BMD at the lumbar spine and total hip between anastrozole and
placebo between years 5 and 7 in women who were not
randomised (osteopenic women in stratum II) or did not receive
risedronate (women with health bone density in stratum I). A
secondary objective was the same as above comparison but in
those who were either randomised (osteopenic women in stratum
II) or received risedronate (osteoporotic women in stratum III) for 5
years of follow-up.
All main results are expressed as percent mean BMD changes at
the total hip or lumbar spine between 5 and 7 years with
corresponding 95% confidence intervals (CI). BMD changes and
differences between treatment groups were assessed using t-tests
for two independent samples with corresponding 95% CI. P values
were two-sided, based on normal approximation and all con-
fidence intervals were at the 95% level. The Bonferroni correction
was applied to account for multiple comparisons. Analyses were
performed using STATA version 13.1 (College Station, Texas USA).
This trial is registered, number ISRCTN31488319.
RESULTS
A total of 1410 postmenopausal women were entered into the
bone substudy with a median follow-up of 10.8 years (IQR 9.5 to
12.7). Seven hundred and sixty-one women were stratified into
stratum I, 500 into stratum II and 149 women into stratum III
(Fig. 1). For those who did not receive risedronate (primary
analysis cohort (grey shaded boxes)), 509 (52.6%) had baseline, 5-
and 7-year DXA scans available. Baseline, 5- and 7-year DXA scans
were available for 188 (49.7%) who received risedronate (with or
without anastrozole) during the 5 years on trial treatments (Fig. 1).
Baseline characteristics for evaluable women are shown in Table 1
according to analysis cohort and main treatment allocation. In the
primary analysis cohort, women in stratum I were significantly
younger (P < 0.001), had higher body mass index (P= 0.003) and
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Fig. 1 CONSORT diagram. CONSORT diagram for all women in the IBIS-II bone substudy (shaded grey area primary analysis cohort).
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stratum II. In the secondary analysis cohort, baseline characteristics
were evenly distributed apart from baseline BMD, which was
significantly higher in women in stratum II (osteopenic) compared to
those in stratum III (osteoporotic) (Table 1).
Primary analysis cohort: anastrozole vs. placebo in women not on
risedronate
Stratum I. Five- and seven-year DXA scans were available for
analysis in 411 women in stratum I (55.9%), 205 anastrozole vs. 206
placebo). Of these, 14 (3.4%) started with bisphosphonate treatment
due to clinicians’ recommendation after 5 years of active follow-up
and were excluded from this analysis. Between years 5 and 7, women
previously randomised to anastrozole had a significant mean
increase in lumbar spine BMD of 1.25% (95% CI 0.73 to 1.77) (P=
0.0004). For women on placebo, the mean BMD change during the
off-treatment period was only 0.14% (95% CI −0.29 to 0.56; P= 0.99)
(Fig. 2). Off-treatment differences at the lumbar spine between
anastrozole and placebo were statistically different (P= 0.0044)
(Supplementary Fig. 1). No significant changes in total hip BMD
between 5 and 7 years was observed for women previously treated
with anastrozole (P= 0.99) (Fig. 2). For those on placebo, a continued
significant BMD decrease at the total hip of−1.35% (95% CI−1.70 to
−0.98; P= 0.0004) after treatment cessation was observed (Fig. 2).
Changes in BMD between treatment arms s in years 5–7 at the total
hip were statistically significant (P= 0.0004) (Supplementary Fig. 1).
Only one patient randomised to placebo developed osteoporosis by
year 7, but she had been osteopenic by year 5 (spinal T-score −2.41).
Stratum II. One hundred and five women (45.1%) had baseline,
5- and 7-year DXA scans available for analysis of which 13 (11.1%)
used a bisphosphonate after five years and were excluded.
Women previously treated with anastrozole (N= 46) had a
significant mean BMD increase at the lumbar spine of 2.58%
(95% CI 1.03 to 4.14) between years 5 and 7 (P= 0.0096) (Fig. 3,
Supplementary Fig. 1). For women on placebo (N= 58), no
significant changes in BMD at the lumbar spine were observed in
this time period (0.41% (95% CI −0.55 to 1.37) (P= 0.99).
Significant differences in BMD changes between women rando-
mised to anastrozole compared to placebo were observed at the
lumbar spine (P= 0.0284) (Supplementary Fig. 1). At the total hip,
a slight increase in BMD (0.44% (95% CI −0.45 to 1.33), P= 0.99)
for women previously treated with anastrozole was observed,
whereas those randomised to placebo showed a continued
significant decrease in BMD during the off-treatment period
(−1.54% (95% CI −2.39 to −0.69) (P= 0.0004) (Fig. 3). The
difference in mean BMD changes between the two treatment
arms was statistically significant (P= 0.012) (Supplementary Fig. 1).
Two women developed osteoporosis at the hip and spine,
respectively (one in each treatment arm).
Secondary analysis cohort: anastrozole vs. placebo in women who
received risedronate
Two hundred and fifty-three of women in stratum II have been
randomised to five years of risedronate (137 anastrozole/
risedronate vs. 116 placebo/risedronate). One hundred and eight
(45.6%) of them had DXA scans at 5 and 7 years available for
analysis. Women previously treated with anastrozole (N= 60) had
a nonsignificant increase in mean lumbar spine BMD of 1.09%
(95% CI 0.23 to 1.96) between 5 and 7 years (P= 0.076)
(Supplementary Fig. 2). For those on placebo (N= 48), a continued
nonsignificant decrease in mean lumbar spine BMD change was
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Fig. 2 Off-treatment bone mineral density changes (%) with associated 95% confidence intervals between 5 and 7 years at the lumbar
spine and total hip for women in stratum I. P values refer to comparison between anastrozole vs. placebo for mean BMD changes between 5
and 7-year timepoints.
Table 1. Baseline characteristics according to stratum and analysis cohort.
No risedronate (primary analysis cohort) Risedronate (secondary analysis cohort)
Stratum I (N= 404) Stratum II (N= 105) P value Stratum II (N= 108) Stratum III (N= 80) P value
Age, median (IQR) 58.6 (54.8–62.2) 60.1 (57.2–64.1) <0.001 59.7 (55.3–64.8) 61.6 (57.2–64.3) 0.15
BMI (kg/m2), median (IQR) 28.5 (25.4–32.6) 26.2 (23.8–30.1) 0.003 25.8 (23.7–29.3) 25.6 (23.4–28.3) 0.61
Previous HRT use (%) 200 (48.7%) 54 (46.2%) 0.63 57 (52.8%) 35 (43.8%) 0.22
Never smokers (%) 227 (55.2%) 74 (63.3%) 0.31 64 (59.3%) 49 (61.3%) 0.38
Hysterectomy (%) 135 (32.9%) 38 (32.5%) 0.94 29 (26.9%) 25 (31.3%) 0.51
Oophorectomy (%) 59 (14.4%) 16 (13.7%) 0.85 20 (18.5%) 6 (7.5%) 0.03
Lowest T-score, median (IQR) −0.37 (−0.87 to 0.22) −1.52 (−1.94 to −1.20) <0.001 −1.63 (−2.02 to −1.23) −2.75 (−3.0 to −2.5) <0.001
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(Supplementary Fig. 2). Significant differences between treatment
arms at the lumbar spine were observed (P= 0.0004). At the total
hip, a significant BMD decrease was observed for women
randomised to placebo (−1.67 (95% CI 2.46 to −0.88) (P=
0.00004) whereas those previously randomised to anastrozole had
a small continued nonsignificant decrease of −0.60% (95% CI
−1.36 to 0.16) (P= 0.48). There were significant differences in
BMD changes at the total hip between anastrozole and placebo (P
= 0.004). A total of six women developed osteoporosis (1 at the
total hip, 5 at the lumbar spine), with 4 women on placebo versus
2 randomised to anastrozole).
For osteoporotic women (N= 80), a significant increase in
lumbar spine BMD was observed for women on anastrozole
(1.92% (0.57 to 3.26), P= 0.024) whereas a small nonsignificant
decrease was seen for women on placebo (−0.54% (95% CI −1.94
to 0.86), P= 0.68) (Supplementary Fig. 2). The difference in mean
BMD changes between treatment arms was statistically significant
(P= 0.04). A similar decrease in total hip BMD between 5 and 7
years was observed for anastrozole (−0.30% (95% CI −1.49 to
0.89) and placebo (−0.57% (95% CI −1.49 to 0.34)) (Supplemen-
tary Fig. 2).
Table 2 shows overall mean BMD changes in all treatment
groups for the overall follow-up period (between baseline and 7
years). Overall, significant differences decrease in mean lumbar
spine BMD at 7 years were observed for women on anastrozole
compared to placebo in stratum I (−3.94% vs. −1.37%, P= 0.0007)
(Table 2). Thirty women in stratum I developed osteopenia after 5
years on anastrozole, of which nine had an improvement in BMD
after stopping with treatment. Similar decrease in total hip BMD
was observed between anastrozole and placebo after 7 years of
follow-up (−5.06% vs. −4.31%, P= 0.7) (Table 2). This translates to
seven women developing osteopenia at the hip on anastrozole, of
which two showed an improvement after stopping with
treatment. In osteopenic women (stratum II) who were rando-
mised to placebo, a nonsignificant improvement in BMD was
observed at the lumbar spine (P= 0.175) and a significant increase
at the total hip (P= 0.0007) in women randomised to risedronate
compared to those who did not receive risedronate (Table 2). In
osteopenic women randomised to anastrozole, the addition of
risedronate significantly improved BMD at the lumbar spine (P=
0.0007) but not at the total hip where change sin BMD were
similar between those received risedronate or not (P= 0.99)
(Table 2). Eight women with osteopenia at baseline who were
randomised to anastrozole developed osteoporosis over 5 years (4
on risedronate and 4 on placebo). Finally, in osteoporotic women
(stratum III), the addition of risedronate did not have any impact
on BMD changes between baseline and 7 years, irrespective of
main randomisation (Table 2).
DISCUSSION
The IBIS-II bone substudy has previously shown that 5 years of
anastrozole used for prevention of breast cancer in postmeno-
pausal women at increased risk of developing the disease was
associated with a greater BMD loss at the lumbar spine and total
hip for women with normal bone health at entry or those with
osteopenia compared to those randomised to placebo.8 Here we
showed that 2 years after stopping treatment with 1 mg/day
anastrozole for 5 years BMD at the lumbar spine improved
whereas BMD at the total hip stabilised over the same time period
in women who did not receive any bisphosphonates. We also
demonstrated that the improvements in BMD at the lumbar spine
were significantly more pronounced for those originally rando-
mised to anastrozole compared with those on placebo. There was
furthermore evidence of partial recovery of total hip BMD for
those on anastrozole, with no further decrease in BMD at this site
once anastrozole treatment was stopped. We also observed an
improvement of BMD at the lumbar spine for osteopenic and
osteoporotic women if they received bisphosphonates during the
trial, but no improvements were observed at the total hip for this
subgroup of women.
Following completion of endocrine therapy, anastrozole
withdrawal was associated with an increase in BMD. This is
probably due to an increase of oestrogen levels and hence a
decrease in bone resorption.5 At the total hip, we found a
stabilisation of BMD for women who were originally randomised
to anastrozole whereas those on placebo showed a continued
BMD loss at the total hip. This is most likely explained by the fact
that age-related BMD loss has been prevented by an increase in
oestrogen levels after stopping the aromatase inhibitor. Oestro-
gen plays an important role in determining bone loss in
postmenopausal women and is strongly linked to cortical bone
loss.13 Overall, the magnitude of BMD loss during the
active treatment period in our study is similar to previous trials
investigating an aromatase inhibitor in the adjuvant14–16 or
preventive setting.5 The Arimidex Tamoxifen Alone or in
Combination (ATAC) trial compared the effectiveness of anastro-
zole to tamoxifen in postmenopausal women.1 Bone mineral
density at the lumbar spine and total hip was measured after 5
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Fig. 3 Off-treatment bone mineral density changes (%) with associated 95% confidence intervals between 5 and 7 years at the lumbar
spine and total hip for women in stratum II. P values refer to comparison between anastrozole vs. placebo for mean BMD changes between 5
and 7-year timepoints.
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stopping treatment.17 In this trial, anastrozole-related bone loss
did not continue into the off-treatment period (2 years after
stopping allocated treatment). Furthermore, there was a
recovery of lumbar spine BMD of 4.0% and absence of further
BMD decline at the total hip (increase of 0.5%). In the second
adjuvant study investigating BMD changes after treatment
cessation, similar improvements were observed.18 The results
from the adjuvant setting are very similar to our findings in the
preventive setting described here.
The clinical significance of a relative improvement at the lumbar
spine and total hip BMD of 1.25% after stopping anastrozole
indicates only a partial recovery at both sites. If we had measured
BMD for all participants after a further 3 years, then there may
have been a full recovery but that is unlikely. When oestrogen is
administered to a postmenopausal woman the increase in BMD
tends to be greatest in the first 2 years and then reaches a
plateau.19 Our results showed no further BMD loss and therefore
there should be no further increase in the risk of fracture in these
postmenopausal women.
The only other study investigating an aromatase inhibitor in the
preventive setting was the MAP.3 trial.4 The nested bone substudy
protocol of the MAP.3 trial5 concentrated on the examination of the
safety of exemestane on bone health, focusing on bone density and
structure. They found that 2 years of exemestane treatment
worsened bone loss in postmenopausal women despite calcium
and vitamin D supplementation. However, they were not able to
assess long-term effects of exemestane on BMD and therefore a
direct comparison between the two prevention studies is not
possible.
The changes after stopping risedronate alone were similar to
those described previously. Watts et al.20 reported the changes in
BMD after stopping a 3-year course of risedronate 5 mg/day in 293
women with postmenopausal osteoporosis. They found that over
a year there was a decrease in lumbar spine (0.8%) and femoral
neck (1.2%). These were slightly larger than observed in the
present study of 0.5% over 2 years at the lumbar spine. Overall,
BMD loss might be expected to be greater at the lumbar spine
than the total hip as it is more metabolically active, but in older
women the development of spinal osteoarthritis can mask bone
loss. The changes in the untreated group in our study were similar
to BMD changes reported in women more than 10 years since the
menopause who have an annual rate of bone loss from the spine
of 0.72% and the total hip of 0.75% per year21 compared to 1.35%
over 2 years in our study.
A strength of this study is that this is the only analysis looking at
the off-treatment effects on BMD changes in the breast cancer
prevention setting. We included a large proportion of women with
normal BMD or osteopenia, with long-term follow-up (7 years).
Women included in this analysis come from a large prevention
study with excellent clinical records and good quality controls for
DXAs. For the primary objective, only women who were either
randomised to or did not receive risedronate were included.
Limitations of our study include that we did not have a complete
DXA data set for all follow-up timepoints (for our primary analysis
set 509/1008 (50.5%)). The main reason for noncomplete datasets
were withdrawal from the main study in most cases due to
anastrozole-related side effects. However, we only included
women in this analysis who had a full set of DXA scans (baseline,
5 and 7 years) and hence all women finished their allocated
treatment. Therefore anastrozole-induced BMD changes during
this time period are the true effect and no selection bias was
introduced. A small number of women were treated with
bisphosphonates after 5 years, but we cannot be sure whether
this represents the true number of women who have taken a
bisphosphonate and therefore this may introduce some bias.
In conclusion, this study is the first to quantify the long-term
impact on BMD in women at increased risk of developing breast

















































































































































































































































































































































































































































































































































































































































Off-treatment bone mineral density changes in postmenopausal women. . .
I Sestak et al.
5
reversible after stopping treatment, particularly at the lumbar
spine. For patients who have been given risedronate for
osteoporosis prevention, bone mineral density improved only at
the lumbar spine but not the total hip. Anastrozole-related bone
loss seems to be manageable and any risk to bone health should
be weighed against overall efficacy and tolerability for the
preventive treatment of at high-risk women.
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